Severe asthma clinic recommendations have been developed to inform the management and treatment of individuals with severe asthma. These resources are useful educational resources, and to inform practice in the clinic setting.
This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of fractional exhaled nitric oxide (FeNO) and eosinophil numbers as biomarkers to inform asthma management, including assessment approaches and interpretation of findings. Asthma is heterogeneous with different disease phenotypes. Recognition and assessment of phenotypes is necessary for targeted therapy. Biomarkers can provide information about mechanisms underlying symptoms.
Access here: https://www.severeasthma.org.au/biomarkers-recommendation/
This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of omalizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.
Access here: https://www.severeasthma.org.au/omalizumab/
This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of mepolizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.
Access here: https://www.severeasthma.org.au/mepolizumab/
This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of dupilumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.
Access here: https://www.severeasthma.org.au/dupilumab/
This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of benralizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.
Access here: https://www.severeasthma.org.au/benralizumab
This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of azithromycin treatment, dosage, screening, monitoring and precautions/adverse effects. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice. Note: The use of macrolide antibiotics, including azithromycin, for the treatment of asthma is off-label.
Access here: https://www.severeasthma.org.au/azithromycin
In some situations, the initiation and continued administration of monoclonal antibodies may be considered in primary care, provided specific conditions are met. This approach may be reasonable where the patient has to travel long distances to the specialist’s clinic or where no ready access to a day procedure unit or outpatient clinic is available. Recommendations on the conditions are included and this information is now included as an Appendix in our Clinical Recommendation documents.
Access here: https://www.severeasthma.org.au/initiation-in-primary-care/
This document was developed by the Centre of Excellence in Severe Asthma. This clinical recommendation was developed to assist clinicians in the management of severe asthma in the context of COVID-19. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.
Access here: https://www.severeasthma.org.au/blog/2020/05/15/covid-19/
People with asthma are more vulnerable to the health impact of bushfire smoke exposure compared to general populations. Exposure to bushfire related fine particulate matter (PM2.5) is associated with an increased risk of hospital admissions, medication use and emergency visits for asthma. Exposure to landscape fire smoke also increases the risk of respiratory mortality including asthma.
Access here:https: //www.severeasthma.org.au/bushfire-smoke/
